Sep 29, 2016
Genocea's Genital Herpes Immunotherapy GEN-003 Demonstrates Significant Reduction of Viral Shedding in Phase 2b Clinical Trial
- Trial achieves primary endpoint - - Dose confirmed for subsequent trials - - Phase 3 expected to start in 2H 2017 - - Company to host confer...
Aug 9, 2016
Genocea Congratulates Jessica Baker Flechtner, Ph.D. for Recognition on 2016's 40 Women To Watch Over 40 List
CAMBRIDGE, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed ...
Events & Presentations
Sep 29, 2016 at 9:00 AM ETListen to webcast